About this trial
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Eligibility criteria
Qualifiers
Patient Inclusion Criteria
Patients with new diagnosis ≥ 60 years of age
An antecedent hematologic disorder
Therapy related-disease
Disqualifiers
Patients with a diagnosis of acute promyelocytic leukemia (APML)
Patients with AML receiving supportive care alone
Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures
Patients seen by a palliative care clinician (MD, DO, APP) during two previous hospitalizations in the six months prior to enrollment
Trial design
Treatments tested in this trial
- Specialty Palliative Care
- Primary Palliative Care
Treatment groups
Sponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Patient-Centered Outcomes Research Institute
Collaborator